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Abstract: The aim was to investigate the induction and repair of radiation-induced DNA double-strand
breaks (DSBs) as a function of the absorbed dose to the blood of patients undergoing PET/CT
examinations with [68Ga]Ga-PSMA. Blood samples were collected from 15 patients before and at four
time points after [68Ga]Ga-PSMA administration, both before and after the PET/CT scan. Absorbed
doses to the blood were calculated. In addition, blood samples with/without contrast agent from
five volunteers were irradiated ex vivo by CT while measuring the absorbed dose. Leukocytes were
isolated, fixed, and stained for co-localizing γ-H2AX+53BP1 DSB foci that were enumerated manually.
In vivo, a significant increase in γ-H2AX+53BP1 foci compared to baseline was observed at all time
points after administration, although the absorbed dose to the blood by 68Ga was below 4 mGy.
Ex vivo, the increase in radiation-induced foci depended on the absorbed dose and the presence of
contrast agent, which could have caused a dose enhancement. The CT-dose contribution for the
patients was estimated at about 12 mGy using the ex vivo calibration. The additional number of DSB
foci induced by CT, however, was comparable to the one induced by 68Ga. The significantly increased
foci numbers after [68Ga]Ga-PSMA administration may suggest a possible low-dose hypersensitivity.
Keywords: DNA double-strand breaks; γ-H2AX; 53BP1; nuclear medicine; dosimetry; Ga-68; PSMA;
PET/CT; contrast agent; prostate cancer
1. Introduction
PET/CT with 68Ga-labelled prostate-specific membrane antigen (PSMA) is a non-invasive
diagnostic technique to image prostate cancer patients with increased PSMA expression [1]. In recent
years, several ligands such as [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA-617, and [68Ga]Ga-PSMA I&T
have been developed for PET/CT diagnostics, demonstrating similar biodistribution and imaging
properties [1]. Among others, [68Ga]Ga-PSMA I&T is of interest, as it can also be labelled with 177Lu
for therapeutic purposes [2,3].
[68Ga]Ga-PSMA PET/CT examinations deliver rather low effective doses [1,2]. Nevertheless,
the ionizing radiation applied may potentially cause DNA double strand breaks (DSBs) whose misrepair
may increase the risk of secondary malignancies. Recently we analyzed, for the therapeutic PSMA
ligand [177Lu]Lu-PSMA I&T, the time- and absorbed dose-dependent induction and repair of DSBs
with a DNA damage focus assay that utilizes immunofluorescent staining with antibodies for γ-H2AX
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and 53BP1 DNA DSB damage markers [4–6] and the analysis of co-localized γ-H2AX+53BP1 foci in
the cell nuclei of peripheral blood leukocytes of prostate cancer patients to assess DSB damage [7].
The time-dependency of the DSB induction is characterized by a linear increase of the number of DSB
foci in the first few hours after administration of the radiopharmaceutical, followed by a phase of
equilibrium between repair and induction of DSBs, and subsequently by predominant repair leading,
in most patients, to a complete decline to baseline foci levels [7–9]. Our group applied this DSB damage
assay successfully in a number of ex vivo and in vivo studies with different therapeutic radionuclides
such as 131I, 177Lu and the radium isotopes 223Ra and 224Ra [7–13].
Up to now, there are few studies on the formation of DNA DSB damage after the diagnostic
application of radiopharmaceuticals. However, the relationship between damage induction and the
absorbed dose has not been investigated so far, making the results of these studies difficult to compare.
Besides three studies concentrating on cardiac imaging [14–16], the focus of these biodosimetry studies
is mainly on effects after [18F]FDG PET(/CT) examinations: Using individual γ-H2AX foci enumeration,
May et al. investigated the formation of DSBs in blood lymphocytes of patients undergoing [18F]FDG
PET/CT examinations [17]. The authors reported a correlation between the CT-induced DSB foci
and the dose-length-product, while patient-specific dosimetry was absent. Schnarr et al. measured
γ-H2AX fluorescence intensity before and after [18F]FDG PET scans and observed a variable response
between the patients [18]. Using γ-H2AX fluorescence intensity measurements, Prasad et al. failed to
reveal a significant increase of the number of induced DSBs in patients undergoing [18F]FDG PET/CT
examinations [19]. Nautiyal et al. used the comet assay and the micronucleus assay to investigate DNA
damage in patients after [18F]FDG PET/CT scans, focusing only on the difference between non-contrast
and contrast-enhanced examinations while data on the dose-dependency of the induced damage were
absent [20].
As this is the first study with patients undergoing [68Ga]Ga-PSMA PET/CT examinations and
no studies on the correlation between DSBs and the absorbed dose to the blood for diagnostic
radiopharmaceuticals have been published so far, the present study serves a three-fold purpose: (i) To
study the induction of DNA damage after irradiation with the high energy positron emitter 68Ga, (ii) to
establish a link between the number of DSBs and the absorbed doses to the blood in the very low-dose
range of <10 mGy, and (iii) to quantify the influence of the CT and the iodinated contrast agent on the
induction of DSBs.
2. Results
2.1. In Vivo Study
2.1.1. Patients and Blood Sampling
Fifteen patients (P1–P15) aged between 56 and 82 years (average: 71 ± 6 years) were enrolled in
this study. The mean administered activity was (140 ± 21) MBq of [68Ga]Ga-PSMA. All patients except
one (P7) showed PSMA uptake. The displayed computed tomography dose index (CTDIvol) of the
whole-body CT was (14.3 ± 2.9) mGy in average. For the low-dose CT of the thorax the CTDIvol was
6.1 mGy for all patients. The demographic, clinical, and scan-related data of all patients are listed as
Supplementary Material in Table S1.
Blood samples for the time points t1, t2, t3, and t4 were taken (18 ± 5) min, (56 ± 10) min,
(90 ± 16) min and (185 ± 15) min after administration. The sample at t2 for patient P8 could not be
taken and is therefore missing. The sample at t2 of patient P7 and the sample at t3 of patient P9 could
not be evaluated. In average, there were (8 ± 3) min between the blood withdrawal and the start of the
processing of the samples, i.e., the isolation of the leukocytes. The time difference between the CT scan
and the start of the processing of the blood samples averaged (19 ± 5) min. For dosimetry calculations,
always the start time of the processing of the samples was used, which was (24 ± 5) min, (64 ± 11) min,
(101 ± 14) min, and (193 ± 15) min after administration for t1, t2, t3, and t4, respectively.
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2.1.2. Dosimetry
For describing the activity retention in the blood, biexponential fit functions were used assuming
only physical decay for the second component. For describing the activity retention in the whole body,
monoexponential fit functions were used.
The average absorbed doses to the blood resulting from 68Ga application at the time points t1, t2,
t3, and t4 were (1.0 ± 0.3) mGy, (1.8 ± 0.5) mGy, (2.1 ± 0.6) mGy, and (2.6 ± 0.7) mGy, respectively. At t2,
the absorbed doses to the blood resulting from 68Ga application was below 3 mGy in all patients; at t4,
it was less than 4 mGy. Total absorbed doses to the blood (t =∞) were not calculated because of the
limited number of sampling time points and the fact that the additional contribution of the CT for all
time points ≥ t3 could not be considered.
The time-dependency of the absorbed dose to the blood resulting from 68Ga application according
to Equation (4) is shown for a selected patient (P14) with average fit parameters in Figure 1A.
The corresponding time-dependency of the absorbed dose rate, defined as the derivative of Equation
(4) over time, is shown in Figure 1B for the same patient.
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2.1.3. Time- and Absorbed Dose-Dependency of γ-H2AX+53BP1 Foci
The mea of the average number of baseline DSB foci per cell in the t0-samples was 0.40 ± 0.17.
The mean of the average number of foci per cell at the time points t1, t2, t3, and t4 was 0.56 ± 0.16,
0.62 ± 0.20, 0.81 ± 0.16, and 0.75 ± 0.19, respectively (Figure 2A). For all four time points, it was
significantly elevated compared to the baseline value at t0. A significant increase of the mean of the
average number of foci was also observed from t1 to t2 and from t2 to t3. From time point t3 to time
point t4, the average number of DSB foci per cell remained constant within the range of the counting
error in eleven of the patients. A clear increase was only observed in one patient (P12) while a clear
decrease was observed in two patients (P6 and P14). For P9, an evaluation was not possible due to the
missing t3-sample. The patient-specific time-dependency of the average number of radiation induced
foci (RIF) per cell is shown in Figure 2B.
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Figure 2. In vivo study ti e-dependency of the average nu ber of foci and radiation induced foci
(RIF). (A) Boxplot of the average number of foci per cell at the five sampling time points t0 to t4.
The mean of the average number of foci at the time points t1, t2, t3, and t4 is significantly elevated
compared to the mean baseline value at t0. A significant increase of the average number of foci was
also observed from t1 to t2 and from t2 and t3. (B) Patient-specific average number of RIF per cell as a
function of the time after administration.
The average number of RIF per cell as a function of the absorbed dose to the blood for the time
points before the CT (only time points t0, t1 and t2) is shown in Figure 3A. In the corresponding dose
range for the t1-samples and the t2-samples, from 0.5 mGy to 2.8 mGy, an increasing number of RIF
was observed. A linear fit to the pooled data resulted in the equation:
Average RIF per Cell = (0.130 ± 0.018) mGy−1 Dbl, Ga-68 + (0.011 ± 0.020); R2 = 0.56 (1)
Figure 3B shows a boxplot of the average number of RIF per cell at the sampling time points t1 to
t4 with the mean absorbed doses to the blood stated in the legend.
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2.2. Ex Vivo Study
2.2.1. Absorbed Dose-Dependency of γ-H2AX+53BP1 Foci
The measured absorbed dose values Dbl, CT were (10.6 ± 0.5) mGy, (20.3 ± 1.1) mGy,
and (31.2 ± 2.1) mGy in average for the three different CT settings D1, D2, and D3, respectively.
The mean of the average number of baseline foci per cell in the non-irradiated D0-sample was
0.28 ± 0.06 in the sample without contrast agent (noCA) and 0.28 ± 0.18 in the sample with contrast
agent (CA). At D1, D2, and D3, the mean of the average number of foci per cell was 0.45 ± 0.10 (noCA)
and 0.46 ± 0.09 (CA), 0.50 ± 0.09 (noCA) and 0.59 ± 0.06 (CA), and 0.62 ± 0.13 (noCA) and 0.81 ± 0.07
(CA), respectively (Figure 4A). However, it is to note that, unlike all other values, the CA-values at
D3 were not normally distributed. The median value of the average number of foci per cell was 0.85
(min.: 0.69; max.: 0.85) in this case. To test for differences between the respective CA and the noCA
groups, we applied paired t-tests. The differences between the two groups were not significant, except
for the highest dose D3. As the values of D3-CA were not normally distributed, we also performed a
Wilcoxon test, which was not significant.
The average number of RIF per cell as a function of the measured dose is shown in Figure 4B.
Linear fits to the pooled volunteer data were performed for the noCA-samples and the CA-samples
separately, resulting in the following linear equations:
Average RIF per Cell (noCA) = (0.010 ± 0.001) mGy−1 Dbl, CT + (0.021 ± 0.022); R2 = 0.78 (2)
Average RIF per Cell (CA) = (0.017 ± 0.002) mGy−1 Dbl, CT + (0.003 ± 0.034); R2 = 0.79 (3)
Applying Akaike information criteria (AIC) and an F-test verified that the two slopes are
statistically different.
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2.2.2. Estimation of the CT-Caused Absorbed Dose to the Blood in the Patient Study
Based on the ex vivo calibration curve for the samples with CA (Equation (3), Figure 4B),
the contribution of the CT to the absorbed dose to the blood in the patient study was estimated at
Dbl, CT = (11.8 ± 4.7) mGy (Figure 3B). For this estimation, the simplifying assumption was made that
the difference in the average number of RIF between time point t2 and time point t3 (∆RIF3→2) was
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exclusively due to the radiation of the CT and that the contribution of the 68Ga can be neglected because
of its very low absorbed dose rate at the time of the CT scan (as shown in Figure 1B). ∆RIF3→2 was
inserted in Equation (3) for each patient separately and individual CT-doses were calculated. In two
patients (P3 and P15) a decrease in RIF after the CT was observed (i.e., ∆RIF3→2 < 0), which would
imply negative CT-doses. These patients were excluded from the analysis. Furthermore, three patients
with missing t2- or t3-samples (P7, P8, and P9) had to be excluded from the analysis. In all other
patients, ∆RIF3→2 was positive and the calculated CT-induced absorbed doses to the blood ranged
from 3.9 mGy up to 19.2 mGy.
3. Discussion
In the current study, the γ-H2AX+53BP1 DSB focus assay was used to investigate DSB induction
and repair in blood leukocytes of patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
and to find a correlation to the absorbed dose to the blood. We observed an increased number of foci
compared to the baseline values even at absorbed doses to the blood in the range between 0.5 mGy
and 2.8 mGy.
The average number of RIF per cell in this very low-dose range was higher than expected
according to a previously established ex vivo calibration curve for the internal irradiation of blood
with the radionuclides 131I and 177Lu [10]. The slope of the latter ex vivo calibration curve
was (0.0147 ± 0.0006) mGy−1 [10], similar to the slopes of in vivo calibration curves established
in several patient studies investigating DSB induction during therapy with 131I (slope of
(0.0117 ± 0.0006) mGy−1) [8], [177Lu]Lu-DOTATATE/DOTATOC (slope of (0.0127 ± 0.0009) mGy−1) [9]
and [177Lu]Lu-PSMA I&T (slope of (0.0122 ± 0.0015) mGy−1) [7]. However, all our previous
studies [7–10] mainly covered the dose range between 6 mGy and 100 mGy. Compared to these results,
the slope in the present study of (0.130 ± 0.018) mGy−1 was approximately ten-fold higher, indicating
that DSB induction might be increased in the very low-dose range <10 mGy, indicative of low-dose
radio hypersensitivity. It is of note, however, that the evaluation of γ-H2AX+53BP1 foci in this very
low-dose range is more error-prone than in higher dose ranges regarding its sensitivity, since the
counting errors increase with a decreasing number of events.
An approximately ten times steeper slope (0.10 foci per mGy) of dose-dependent γ-H2AX foci in
the low-dose region (below 10 mGy) was also reported by Beels et al., however, for blood samples
irradiated with X-rays but not for samples that were exposed to 60Co γ-rays [21]. A similar low-dose
hypersensitive response is also described in two other studies published by Beels et al. [22,23].
The authors depict a biphasic behavior of the dose response: A steep linear increase in γ-H2AX foci
up to 6 mGy [22] or 10 mGy [23], followed by more flat linear increase at higher doses. In a study by
Vandevoorde et al. a low-dose hypersensitivity has also been observed when using the quantification
of γ-H2AX foci to investigate DNA damage induced by CT X-rays in pediatric patients [24]. Despite
very low blood doses between 0.14 mGy and 8.85 mGy, there was a statistically significant increase of a
median of 0.13 foci per cell after the examinations, which was considerably higher than expected from
the extrapolation of high-dose behavior based on a linear-no-threshold hypothesis [24]. One possible
explanation for the increased number of DSBs for very low doses are bystander effects in cells that
were not directly hit [25]. Alternatively, the relatively high amount of DSBs could also be related to a
reduced repair efficacy at very low doses, as reported in several studies investigating DNA DSB repair
after low-dose X-ray irradiation of cultured human fibroblasts and mouse tissues [26–28]. This would
lead to enrichment and persistence of foci induced in this dose range.
Up to now, there is no other patient study correlating DNA damage to absorbed doses to the blood
in this diagnostic low-dose range, but there are few other studies [17–19] investigating DSB formation
after [18F]FDG application reporting varying outcomes. The first study investigating formation and
repair of PET/CT-induced DSBs in vivo was conducted by May et al. [17]. They analyzed γ-H2AX foci
in 33 patients receiving 138-354 MBq [18F]FDG and one or two diagnostic CT scans and report that a
median of 0.11 foci per cell and 0.17 foci per cell was induced by the [18F]FDG and the whole-body CT,
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respectively. The considerable higher amount of foci induced by the CT is in good agreement with
our study, as we observed a median increase of 0.15 foci per cell (18 ± 5) min after [68Ga]Ga-PSMA
I&T administration and a median increase of 0.21 foci per cell when comparing the foci number
directly after the CT (t3) to the foci number directly before the CT (t2). However, since a different
radiopharmaceutical was used and no dosimetry was performed by May et al. the results are difficult
to compare. Furthermore, the different protocol for leukocyte isolation and fixation and the fact that,
in our study, co-localizing γ-H2AX+53BP1 foci were evaluated, also impedes a direct comparison of
foci numbers. In addition, May et al. observed a significant correlation between the CT-induced DSBs
and the dose-length-product. In the present study, there was no significant correlation.
In contrast to May et al. other authors, who measured γ-H2AX fluorescence intensity in patients’
lymphocytes both before and after [18F]FDG application, reported that they did not find significant
changes [18,19]. Schnarr et al. observed a varied response among ten patients when measuring γ-H2AX
fluorescence intensity by flow cytometry before and after [18F]FDG PET scans [18]. Prasad et al. also
used flow cytometry to measure γ-H2AX fluorescence intensity in the lymphocytes of 25 patients and
reported an increase in the signal after the PET/CT scan that was, however, not significant because
of a high inter-individual variation [19]. This indicates that the evaluation of γ-H2AX fluorescence
intensities might not be sensitive enough to assess DNA damage after exposures to very low absorbed
doses and that, as shown in our current study, the quantification of DSB foci seems to be a more suitable
approach in this dose range.
In a recent study, Nautiyal et al. investigated the effect of ionizing radiation in patients undergoing
non-contrast and contrast-enhanced [18F]FDG PET/CT examinations using both comet assay and
micronucleus assay [20]. They did not investigate the dose-dependency of the induced DNA damage
either, but focused on the difference between a patient group that received a contrast agent and a
corresponding non-contrast group. As a result, they report a significant increase in DNA damage in the
contrast group compared to the non-contrast group [20], which is in accordance with the observations
made in the present ex vivo study.
Many further studies used the γ-H2AX assay both ex vivo and in vivo for investigation of DNA
damage in blood lymphocytes induced during CT examinations and, in particular, to investigate
the effect of iodinated contrast agents [23,29–36]. In agreement with the results of our ex vivo study,
the majority of these studies report an increase of DNA damage in the contrast media-enhanced
samples. Despite the findings in some of the ex vivo studies that this increase is only significant for
high concentrations of the iodinated contrast agents used (up to 50 mg mL−1) or high radiation doses
(up to 1 Gy) but not in a range that is clinically relevant for diagnostic procedures [30,34], many patient
studies show that there is an 30 to 107% increase in DNA damage when contrast agents are applied
compared to non-contrast enhanced examinations [31,32,34–36].
In our ex vivo study, we matched the CT settings and the concentration of the contrast agent
as closely as possible with parameters comparable to the patient examinations. The absorbed dose
range was chosen to be between 10 mGy and 30 mGy and the contrast agent concentration was chosen
to be 5.55 mg mL−1 iodine concentration in the blood. A tendency of an increased amount of DNA
DSBs was observed for all absorbed doses. Comparing the slope values of the ex vivo calibration
curves established in this study, the slope for the CA-samples was 1.7 times higher than the slope for
the noCA-samples. The increase of DNA damage after the application of iodinated contrast agents
could be caused by increased energy deposition, as suggested by Harbron et al. who performed Monte
Carlo modelling to obtain dose enhancement factors (DEFs) to blood for different blood vessel models
and iodine concentrations [37]. For an iodine concentration of 5.0 mg mL−1, (which is similar to our
experiments) they calculated a DEF of 1.63 for the intraluminal part of an artery model (120 kV tube
voltage) [37]. Jost el al. also calculated DEFs for the same iodine concentration of 5.0 mg mL−1 and
report a DEF of 1.56 [30]. The results of both groups are in excellent agreement with the experimental
findings of our current study that suggest a DEF of 1.7.
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Comparing the contribution of the CT to the absorbed dose to the blood in patients, which was
(11.8 ± 4.7) mGy in average, with the contribution of the 68Ga leads to the conclusion that, for this
hybrid imaging setup, the major contribution to the absorbed dose to the blood is caused by CT.
However, the assessment of the CT-caused absorbed dose to the blood based on our ex vivo experiments
is a simplification with some limitations: First, it is not possible to ensure that each t3-sample was
processed at the exact time when the maximum of RIF induced by the CT was reached. The average
time difference between the CT scan and the processing of the blood samples was (19 ± 5) min,
which generally matches the observation that the maximum of γ-H2AX+53BP1 foci is reached 15 min
to 30 min after external irradiation [4,6,38]. However, a variable time difference can be the reason
for the varying number of RIF after the CT. Especially the decrease in RIF after the CT in patient P3
may be ascribed to insufficient time for maximum foci induction, since this was the patient with the
minimum time difference between the CT scan and the blood sample processing of only 9 min. Aside
from that, DSB repair kinetics are known to vary between individual patients [7–9]. Second, we cannot
exclude that there is still DSB induction due to [68Ga]Ga-PSMA uptake, despite the low absorbed
dose rate to the blood at the time of the CT scan (see Figure 1B). Third, in our ex vivo study we only
covered the dose range between 10 mGy and 30 mGy, since this was the dose range anticipated from
the CTDIvol values of a whole-body CT with the settings used in this study. However, we cannot
exclude completely that the number of RIF in the low-dose range may be higher than expected from
the extrapolation, as observed after low-dose 68Ga exposure. This could have led to an overestimation
of the CT-caused absorbed dose to the blood. The fact that the estimated value for the CT-caused
absorbed dose to the blood is well in line with the average displayed CTDIvol of the whole-body CT of
(14.3 ± 2.9) mGy renders an overestimation, however, rather unlikely.
4. Materials and Methods
4.1. Ethics Committee Approval and Patient Consent
The research plan was presented to the Ethics Committee of the Medical Faculty of the University
of Würzburg, Germany. The Ethics Committee approved the study stating that there were no objections
to the conduct of the study (Az: 209/14 and 165/14). All procedures performed in studies involving
human participants were in accordance with the ethical standards of the Ethics Committee of the
Medical Faculty of the University of Würzburg and with the principles of the 1964 Declaration of
Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained
from all individual participants included in the study.
4.2. In Vivo Study
4.2.1. Patients
For the in vivo study, 15 prostate cancer patients (P1–P15) referred to our center for diagnostic
PET/CT examinations were enrolled. The indications for the examinations were primary or re-staging,
PSA-relapse or progressive disease.
All patients received a standard activity of 150 MBq of [68Ga]Ga-PSMA I&T (SCINTOMICS
GmbH, Munich, Germany) that was intravenously administered approximately one hour before the
PET/CT scan (Biograph mCT, Siemens Healthineers, Erlangen, Germany). The radiolabeling process
and quality control of the radiopharmaceutical was performed according to our standard operation
procedure analogous to the method described by Herrmann et al. [2]. As a standard procedure,
all patients received orally 10 mg furosemide (Lasix®, Sanofi-Aventis, Frankfurt, Germany) to reduce
the absorbed dose to the bladder and 30 mL Peritrast® (Dr. Franz Köhler Chemie GmbH, Bensheim,
Germany) to enhance the CT contrast of the intestinal tract. Directly before the CT examination, 1 mL
per 1 kg body weight of an iodinated contrast agent (Ultravist®-370, Bayer, Leverkusen, Germany)
was administered intravenously. CT scans were performed at 120 kV with 210 mAs reference and
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an anatomy-based tube current modulation (Care Dose). Additionally, a low-dose CT of the thorax
(120 kV, 80 mAs) was performed.
4.2.2. Blood Sampling and External Dose Rate Measurements
Blood samples were taken prior (t0; for the determination of the number of individual baseline
foci) and at four time points after the administration of [68Ga]Ga-PSMA I&T. The nominal sampling
time points were: approximately 15 min after administration (t1), directly before the PET/CT scan (t2;
approx. 60 min after administration), directly after the PET/CT scan (t3), and approx. 90–120 min
after the PET/CT scan (t4). Li-Heparin blood collecting tubes (S-Monovette®, Sarstedt, Nümbrecht,
Germany) were used for the blood withdrawals.
In order to determine the contribution of the γ-radiation to the absorbed dose to the blood,
3–4 external dose rate measurements of each patient were performed after the administration of
the activity, usually directly before or directly after each blood withdrawal. For this, a dose rate
meter (6150AD®, automess GmbH, Ladenburg, Germany) was used to measure the dose rate in 1 m
distance from the patient. The value of the first measurement that was performed prior to the first
post-administration void or defecation by the patient, was decay corrected to the time of administration
and normalized to 1, corresponding to 100% uptake.
4.2.3. Activity Quantification
For activity quantification, an aliquot of each blood sample was measured in a calibrated
high-purity germanium detector (Canberra, Rüsselsheim, Germany) and the γ-emission line at 511 keV
(emission probability of 178%) was evaluated. The counting efficacy of the germanium detector was
ascertained by measuring several NIST- and NPL-traceable standards. The measured number of counts
at 511 keV was decay-corrected to the start time of the measurement. Then, the corresponding activity
value was decayed to the time point of the blood withdrawal.
4.2.4. Calculation of the Absorbed Doses to the Blood Related to 68Ga Application
Biexponential and monoexponential fit functions were used to model the time curves for the
activity retention in the blood and in the whole-body, respectively, in each patient. Time-integrated
activity coefficients (TIACs) for the activity concentration in the blood (τmL of bl (t) in hours per mL)
and for the whole-body (τwb (t) in hours) were attained by integrating the time-activity fit functions
over time, up to the time point t when the processing of the blood samples (i.e., the isolation of the
leukocytes) started.
The contribution of the 68Ga to the absorbed dose to the blood Dbl, Ga-68 (t) as a function of time
was calculated according to the Medical Internal Radiation Dose (MIRD) formalism [39], in analogy to
Eberlein et al. [9], using the following equation:
Dbl, Ga-68 (t) = A0 (425 Gy mL GBq−1 h−1 · τmL of bl (t) + 0.0459 Gy kg2/3 GBq−1 h−1 ·wt−2/3 τwb (t)) (4)
Here, A0 is the administered activity in GBq and wt is the weight of the patient in kg. To calculate
the S-value for the self-irradiation of the blood, it was assumed that all β-energy is deposited in the
blood (emission data taken from [40]), neglecting the contribution of the γ-radiation. For the calculation
of the whole-body contribution, only the γ-radiation was considered and the weight-adapted S-value
was taken from OLINDA/EXM [41]. A more detailed derivation of Equation (4) is given in the
Supplementary Material of reference [9].
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4.3. Ex Vivo Study
4.3.1. Blood Sampling and Irradiation
For the ex vivo study, five healthy volunteers (V1–V5) aged between 23 and 61 years were included
in the study. A total of 36 mL blood was taken from each volunteer using Li-Heparin blood collecting
tubes (S-Monovette®, Sarstedt). The blood was subsequently split into eight 4.5 mL aliquots and
pipetted into 5 mL round bottom tubes (Sarstedt). Directly before the irradiation, four of the aliquots
were supplemented with 67.5 µL contrast agent (Ultravist®-370, Bayer), while the same amount of
phosphate buffered saline (PBS) was added to the other four samples. The concentration of the contrast
agent (15 µL per mL blood) was chosen to match the concentration in patients’ blood assuming a blood
volume of 5 L for a patient of 75 kg bodyweight.
For the irradiation in the CT scanner, one blood sample with contrast agent (CA) and one blood
sample without contrast agent (noCA) were placed at defined positions on the patient bench. All CT
parameters were chosen according to the patient study. The tube voltage was kept constant at
120 kV and only the tube current time product was varied to achieve three different absorbed doses
Dbl, CT = D1 (60 mAs), Dbl, CT = D2 (110 mAs) and Dbl, CT = D3 (180 mAs). For the determination of
the number of individual baseline foci, one pair of samples was not irradiated (D0).
To mimic the patient study, the isolation of the leukocytes from the blood samples started 20 min
after the irradiation in the CT.
4.3.2. Absorbed Dose Measurements
A 3D-printed blood phantom was constructed to fit exactly in the round bottom tubes (Sarstedt)
used for the irradiation of the blood samples. The density of the material (polyamide PA 12; 1.01 g cm−3)
was chosen to be similar to the density of blood. In the middle of the phantom, a cavity was designed
so that an ionization chamber (type 23323, PTW, Freiburg, Germany) could be positioned centrally in
the tube. To ensure a precise measurement, the ionization chamber was first irradiated with a high
tube current time product (240 mAs), the low-dose-setting (0.5 to 58 mGy) was chosen and a zero
adjustment was performed before each experiment. For every irradiation process, the tube with the
blood phantom and the ionization chamber was placed at a defined position on the patient bench next
to the two blood samples. The dose value (Dbl, CT) displayed on a calibrated dosimeter (UNIDOS,
PTW) connected to the ionization chamber was noted for every irradiation process.
4.4. Evaluation of DNA Damage
The processing of the blood samples and the evaluation of co-localizing γ-H2AX+53BP1 DSB foci
followed the protocol described by Eberlein et al. [9]. Briefly, leukocytes (more precisely: peripheral
blood mononuclear cells) were separated by density centrifugation in BD Vacutainer CPT tubes
(BD, Heidelberg, Germany), twice washed with PBS, fixed in 70% ethanol and stored at −20 ◦C.
Immunofluorescence staining and DSB foci analysis [42] was performed at the Bundeswehr Institute of
Radiobiology in Munich, Germany.
In each sample, co-localizing γ-H2AX+53BP1 foci were counted in 100 cells by an experienced
investigator (HS). The evaluation of co-localizing foci only was chosen since this avoids counting
of false positive γ-H2AX foci and increases the accuracy of the assay [43]. To calculate the average
number of radiation-induced DSB foci (RIF) per cell, the average number of the individual baseline foci
per cell was subtracted from the average number of the counted foci per cell in the irradiated samples.
4.5. Statistical Analysis
OriginPro 2017 (Origin Lab Corporation, Northampton, MA, USA) was used for plotting and
analysis of data, and for statistical evaluation. The Shapiro-Wilk-test was used to test normality
distribution. To test for differences between two dependent groups of normally distributed data, paired
t-tests were performed. If normality was rejected, the Wilcoxon test was applied. To compare slopes of
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linear fits, Akaike information criteria (AIC) and an F-test were performed. Generally, results were
considered significant for p < 0.05.
Assuming a Poisson-distribution, the standard deviation of the foci count was calculated. For the
calculation of the standard deviation of the average number of RIF per cell, error propagation was
performed, considering additionally the standard deviation of the baseline foci count. In general,
standard deviations are given for all mean values. For fit parameters, standard errors are stated.
5. Conclusions
By correlating DNA damage in blood leukocytes quantified by using the γ-H2AX+53BP1 DSB
focus assay with the absorbed doses to the blood after administration of [68Ga]Ga-PSMA I&T, we were
able to show that even at very low absorbed doses to the blood of less than 3 mGy, the number of DSBs
in the blood is significantly increased compared to baseline. The numbers were higher as expected
from extrapolations of the results of previous studies that focused on a higher dose range.
Whole-body CT that was performed in combination with the PET acquisition also induced a
significant increase of RIF that was presumably related to a CT-induced absorbed dose of about 12 mGy.
This indicates that, for this hybrid imaging scenario, the contribution of the CT to the absorbed dose to
the blood is higher than that of the 68Ga, even though the DNA damage induction is comparable.
In conclusion, our results emphasize the need for more investigations on DSB induction and
repair after internal irradiation in the very low dose range of diagnostic examinations. So far, there are
only few studies with informative results in this area. This might be due to the fact that the very low
dose range is difficult to assess and most biodosimetric assays are not sensitive enough to provide
statistically significant results. The γ-H2AX+53BP1 focus assay, in contrast, proves as a useful tool for
the quantification of radiation-induced DSBs even after internal exposures to absorbed doses of less
than 10 mGy.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/2/388/s1:
Table S1: Patient demographic, clinical and scan-related data.
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